檢索結果 - Laura van ‘t Veer

Refine Results
  1. 1
    Prediction of adjuvant chemotherapy benefit in endocrine responsive, early breast cancer using multigene assays

    Prediction of adjuvant chemotherapy benefit in endocrine responsive, early breast cancer using multigene assays 由 Kathy S. Albain, Soonmyung Paik, Laura van’t Veer

    出版 2009
    獲取全文
    Revisão
    加到收藏夾
    Saved in:
  2. 2
    The MINDACT trial: The first prospective clinical validation of a genomic tool

    The MINDACT trial: The first prospective clinical validation of a genomic tool 由 Fátima Cardoso, Martine Piccart, Laura Van't Veer, Emiel J. Rutgers

    出版 2007
    獲取全文 獲取全文
    Artigo
    加到收藏夾
    Saved in:
  3. 3
    Gene expression profiling may improve diagnosis in patients with carcinoma of unknown primary

    Gene expression profiling may improve diagnosis in patients with carcinoma of unknown primary 由 John Bridgewater, Ryan K. van Laar, Arno Floore, Laura van’t Veer

    出版 2008
    獲取全文 獲取全文
    Artigo
    加到收藏夾
    Saved in:
  4. 4
    Gene Co-Expression Modules as Clinically Relevant Hallmarks of Breast Cancer Diversity

    Gene Co-Expression Modules as Clinically Relevant Hallmarks of Breast Cancer Diversity 由 Denise M. Wolf, Marc E. Lenburg, Christina Yau, Aaron Boudreau, Laura van ‘t Veer

    出版 2014
    獲取全文 獲取全文
    Artigo
    加到收藏夾
    Saved in:
  5. 5
    Cost-Effectiveness of Treatment Strategies for BRAF-Mutated Metastatic Melanoma

    Cost-Effectiveness of Treatment Strategies for BRAF-Mutated Metastatic Melanoma 由 Patti Curl, Igor Vujic, Laura van ‘t Veer, Susana Ortiz‐Urda, James G. Kahn

    出版 2014
    獲取全文 獲取全文
    Artigo
    加到收藏夾
    Saved in:
  6. 6
    TATA-binding protein and the retinoblastoma gene product bind to overlapping epitopes on c-Myc and adenovirus E1A protein.

    TATA-binding protein and the retinoblastoma gene product bind to overlapping epitopes on c-Myc and adenovirus E1A protein. 由 Guus Hateboer, H. T. Marc Timmers, AK Rustgi, Marc Billaud, Laura van ‘t Veer, René Bernards

    出版 1993
    獲取全文
    Artigo
    加到收藏夾
    Saved in:
  7. 7
    E2F-5, a New E2F Family Member That Interacts with p130 In Vivo

    E2F-5, a New E2F Family Member That Interacts with p130 In Vivo 由 E. Marielle Hijmans, P. Mathijs Voorhoeve, Roderick L. Beijersbergen, Laura van ‘t Veer, René Bernards

    出版 1995
    獲取全文
    Artigo
    加到收藏夾
    Saved in:
  8. 8
    Contralateral prophylactic mastectomy: A narrative review of the evidence and acceptability

    Contralateral prophylactic mastectomy: A narrative review of the evidence and acceptability 由 Josien C.C. Scheepens, Laura van ‘t Veer, Laura J. Esserman, Jeffrey Belkora, Rita A. Mukhtar

    出版 2021
    獲取全文 獲取全文
    Revisão
    加到收藏夾
    Saved in:
  9. 9
    Circulating tumor nucleic acids: biology, release mechanisms, and clinical relevance

    Circulating tumor nucleic acids: biology, release mechanisms, and clinical relevance 由 Pavel Stejskal, Hani Goodarzi, Josef Srovnal, Marián Hajdúch, Laura van ‘t Veer, Mark Jesus M. Magbanua

    出版 2023
    獲取全文 獲取全文
    Revisão
    加到收藏夾
    Saved in:
  10. 10
    Identification of Bmi1-interacting proteins as constituents of a multimeric mammalian polycomb complex.

    Identification of Bmi1-interacting proteins as constituents of a multimeric mammalian polycomb complex. 由 Mark J. Alkema, Marieke Bronk, Els Verhoeven, Arie P. Otte, Laura van ‘t Veer, A Berns, Maarten van Lohuizen

    出版 1997
    獲取全文 獲取全文
    Artigo
    加到收藏夾
    Saved in:
  11. 11
    Identification of a low-risk subgroup of HER-2-positive breast cancer by the 70-gene prognosis signature

    Identification of a low-risk subgroup of HER-2-positive breast cancer by the 70-gene prognosis signature 由 Michael Knauer, Fátima Cardoso, Jelle Wesseling, Philippe L. Bédard, Sabine C. Linn, Emiel J. Rutgers, Laura van ‘t Veer

    出版 2010
    獲取全文 獲取全文
    Artigo
    加到收藏夾
    Saved in:
  12. 12
    Worse Breast Cancer Prognosis of BRCA1/BRCA2 Mutation Carriers: What's the Evidence? A Systematic Review with Meta-Analysis

    Worse Breast Cancer Prognosis of BRCA1/BRCA2 Mutation Carriers: What's the Evidence? A Systematic Review with Meta-Analysis 由 Alexandra J. van den Broek, Marjanka K. Schmidt, Laura van ‘t Veer, Rob A.�E.�M. Tollenaar, Flora E. van Leeuwen

    出版 2015
    獲取全文 獲取全文
    Revisão
    加到收藏夾
    Saved in:
  13. 13
    Comparison of prognostic gene expression signatures for breast cancer

    Comparison of prognostic gene expression signatures for breast cancer 由 Benjamin Haibe‐Kains, Christine Desmedt, Fanny Piette, Marc Buyse, Fátima Cardoso, Laura van’t Veer, Martine Piccart, Gianluca Bontempi, Christos Sotiriou

    出版 2008
    獲取全文 獲取全文
    Artigo
    加到收藏夾
    Saved in:
  14. 14
    Expression profiling predicts outcome in breast cancer

    Expression profiling predicts outcome in breast cancer 由 Laura van ‘t Veer, Hongyue Dai, Marc J. van de Vijver, Yudong D. He, Augustinus A. M. Hart, René Bernards, Stephen Friend

    出版 2002
    獲取全文 獲取全文
    Carta
    加到收藏夾
    Saved in:
  15. 15
    Tamoxifen resistance by a conformational arrest of the estrogen receptor α after PKA activation in breast cancer

    Tamoxifen resistance by a conformational arrest of the estrogen receptor α after PKA activation in breast cancer 由 Rob Michalides, Alexander Griekspoor, Astrid Balkenende, Desirée Verwoerd, Lennert Janssen, Kees Jalink, Arno Floore, Arno Velds, Laura van 't Veer, Jacques Neefjes

    出版 2004
    獲取全文 獲取全文
    Artigo
    加到收藏夾
    Saved in:
  16. 16
    N-ras mutations in human cutaneous melanoma from sun-exposed body sites.

    N-ras mutations in human cutaneous melanoma from sun-exposed body sites. 由 Laura van ‘t Veer, Boudewijn Burgering, Rogier Versteeg, A J Boot, D. J. Ruiter, Susanne Osanto, Peter I. Schrier, Johannes L. Bos

    出版 1989
    獲取全文
    Artigo
    加到收藏夾
    Saved in:
  17. 17
    A protocol for building and evaluating predictors of disease state based on microarray data

    A protocol for building and evaluating predictors of disease state based on microarray data 由 Lodewyk F.A. Wessels, Marcel J. T. Reinders, A.A.M. Hart, Cor J. Veenman, H. Dai, Yudong D. He, Laura van ‘t Veer

    出版 2005
    獲取全文 獲取全文
    Artigo
    加到收藏夾
    Saved in:
  18. 18
    Multi-gene panel testing for hereditary cancer predisposition in unsolved high-risk breast and ovarian cancer patients

    Multi-gene panel testing for hereditary cancer predisposition in unsolved high-risk breast and ovarian cancer patients 由 James M. Ford, Sophie Adams, Taylor Sittler, Jeroen van den Akker, Salina Chan, Ofri Leitner, Lauren Ryan, Elad Gil, Laura van ’t Veer

    出版 2017
    獲取全文 獲取全文
    Artigo
    加到收藏夾
    Saved in:
  19. 19
    A combined oncogenic pathway signature of<i>BRAF</i>,<i>KRAS</i>and<i>PI3KCA</i>mutation improves colorectal cancer classification and cetuximab treatment prediction

    A combined oncogenic pathway signature of<i>BRAF</i>,<i>KRAS</i>and<i>PI3KCA</i>mutation improves colorectal cancer classification and cetuximab treatment prediction 由 Sun Tian, Iris Simón, Vı́ctor Moreno, Paul Roepman, Josep Tabernero, Mireille H.J. Snel, Laura van’t Veer, Ramón Salazar, René Bernards, Gabriel Capellà

    出版 2012
    獲取全文 獲取全文
    Artigo
    加到收藏夾
    Saved in:
  20. 20
    Additional prognostic value of the 70-gene signature (MammaPrint®) among breast cancer patients with 4–9 positive lymph nodes

    Additional prognostic value of the 70-gene signature (MammaPrint®) among breast cancer patients with 4–9 positive lymph nodes 由 Mahasti Saghatchian, Stella Mook, Giancarlo Pruneri, Giuseppe Viale, Annuska M. Glas, Sylvie Guérin, Fátima Cardoso, Martine Piccart, Thomas Tursz, Suzette Delaloge, Laura van’t Veer

    出版 2013
    獲取全文
    Artigo
    加到收藏夾
    Saved in:

檢索工具: